Estudio ARAPOC: prevalencia de síntomas respiratorios y enfermedad obstructiva crónica en población general

http://www.elsevier.es/es-revista-atencion-primaria-27-articulo-estudio-arapoc-prevalencia-sintomas-respiratorios-90431671

Videos para pacientes adultos con Fibrosis quística

http://www.rbht.nhs.uk/patients/condition/cystic-fibrosis/patient-information/films/

Hablemos sobre EPOC: ¿La conocías?

Sesión clínica del centro de salud San Blas de Alicante :

http://sesionessanblas.blogspot.com.es/2015/06/hablemos-sobre-epoc-la-conocias.html

EPOC: la década prodigiosa. Implicaciones para su diagnóstico, prevención y tratamiento

http://www.elsevier.es/es-revista-medicina-clinica-2-articulo-enfermedad-pulmonar-obstructiva-cronica-decada-90419488?login=ok

CADIME : Tratamiento de mantenimiento del asma en adultos

http://www.cadime.es/es/boletin_terapeutico_andaluz.cfm?bid=182#.VYKtTVXtlBd

EUROPEAN MEDICINES AGENCY (EMA) : inicio de la revisión de los corticoides inhalados en la EPOC

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Inhaled_corticosteroids_for_chronic_obstructive_pulmonary_disease/human_referral_prac_000050.jsp&mid=WC0b01ac05805c516f

The European Medicines Agency (EMA) has started a review of inhaled corticosteroid-containing medicines used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term inflammatory disease of the lungs in which the airways and air sacs in the lungs become damaged or blocked. Corticosteroids are widely used in the European Union (EU) to treat COPD and are usually taken by inhalation using an inhaler device.

The review of inhaled corticosteroid-containing medicines has been requested by the European Commission to evaluate the risk of pneumonia (inflammation of the lungs) when these medicines are used for COPD. The risk of pneumonia with these medicines is known and was first identified in 2007 when a study showed that patients treated with an inhaled corticosteroid, fluticasone, were at higher risk of developing pneumonia than those given placebo (dummy treatment)*. Since then, new studies of individual inhaled corticosteroids and combined study results (meta-analyses) on the class of inhaled corticosteroids have provided further data on the risk of pneumonia and it was considered necessary that a thorough review be performed to further characterise this risk.

EMA will now review all available data on the risk of pneumonia with inhaled corticosteroids for COPD and consider the need to update the existing prescribing advice across the EU.

Receta para dejar de fumar

http://www.semanasinhumo.es/upload/file/materiales/Receta_web_XVI_SSH.pdf

'iCoach' : una 'App' para dejar de fumar

http://www.infosalus.com/salud-investigacion/noticia-mas-442000-europeos-utilizan-icoach-app-dejar-fumar-20150529141102.html?utm_content=bufferba585&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

¿ Cuándo prescribir azitromicina ?

http://www.australianprescriber.com/magazine/38/3/87/9

Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and excellent tissue penetration.

It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used in preference to other macrolides for some sexually transmitted and enteric infections.

Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose.

Potential major adverse effects include cardiovascular arrhythmias and hearing loss. Macrolide resistance is also a problem, as are interactions with commonly prescribed drugs.

Andalucía sin tabaco

http://livestream.com/easptv/AndaluciaSinTabaco/videos/88953036?t=1433160675

Nueva edición de “Diálogos EASP”, centrada esta vez en la lucha contra el tabaquismo en la comunidad autónoma andaluza. 
El director del Plan Integral de Tabaquismo de Andalucía (PITA), Daniel Jesús López Vega y el director de la Unidad de Gestión Clínica Rodríguez Arias de San Fernando (Cádiz), Vidal Samuel Barchillón nos hablan del trabajo que se ha desarrollado por parte de profesionales y administración para ayudar a miles de personas a dejar de fumar y establecer hábitos de vida más saludables.

Broncodilatadores para la EPOC : cuadro resumen

https://mileon.wordpress.com/2015/05/28/broncodilatadores-para-la-epoc-cuadro-resumen/

El Dr. Borrego, adjunto del servicio de Medicina Interna del Hospital de León, ha realizado una actualización sobre el anterior cuadro de broncodilatadores, incluyendo los nuevos productos que se han comercializado en los últimos meses.

Actividad física en pacientes con EPOC : The PROactive instruments

http://erj.ersjournals.com/content/early/2015/05/28/09031936.00183014.long

Daily and clinical visit “PROactive physical activity in COPD” instruments are hybrid tools combining a short patient-reported outcome questionnaire and two activity monitor variables which provide simple, valid and reliable measures of physical activity in COPD patients.

Rinitis alérgica : guía de práctica clínica

http://oto.sagepub.com/content/152/1_suppl/S1.long

This clinical practice guideline was undertaken to optimize the care of patients with AR by addressing quality improvement opportunities through an evaluation of the available evidence and an assessment of the harm-benefit balance of various diagnostic and management options.